| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
44,215,000 |
| Market
Cap: |
4.11(M) |
| Last
Volume: |
17,424 |
Avg
Vol: |
59,181 |
| 52
Week Range: |
$0.06 - $0.2089 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Enzon Pharmaceuticals is engaged in existing licensing arrangements with other companies primarily related to sales of certain drug products that utilize Co.'s proprietary technology. Co. has a marketing agreement relating to the drug Vicineum.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
99,550 |
99,550 |
| Total Buy Value |
$0 |
$0 |
$13,910 |
$13,910 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Horak Ivan D |
EVP, R&D, Chief Scientific Off |
• – – |
2009-04-03 |
4 |
S |
$6.12 |
$43,054 |
D/D |
(7,035) |
122,924 |
|
- |
|
| Horak Ivan D |
EVP, R&D, Chief Scientific Off |
• – – |
2009-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,860 |
128,977 |
|
- |
|
| Delcampo Ralph |
EVP, Technical Operations |
• – – |
2009-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,600 |
139,604 |
|
- |
|
| Buchalter Jeffrey H |
Chairman of the Board & CEO |
• • – |
2009-04-03 |
4 |
D |
$6.12 |
$165,307 |
D/D |
(27,011) |
521,653 |
|
- |
|
| Buchalter Jeffrey H |
Chairman of the Board & CEO |
• • – |
2009-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
59,430 |
548,664 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2009-01-17 |
4 |
S |
$6.33 |
$65,237 |
D/D |
(10,306) |
108,806 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2009-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
26,667 |
119,112 |
|
- |
|
| Tooman Craig A |
Exec VP Finance, CFO |
• – – |
2008-11-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
119,122 |
|
- |
|
| Horak Ivan D |
EVP, R&D, Chief Scientific Off |
• – – |
2008-11-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,250 |
108,250 |
|
- |
|
| Buchalter Jeffrey H |
Chairman, CEO & President |
• • – |
2008-11-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
36,000 |
489,234 |
|
- |
|
| Davit Paul Stephen |
Exec. Vice Pres. HR |
• – – |
2008-11-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
60,603 |
|
- |
|
| Delcampo Ralph |
EVP - Technical Operations |
• – – |
2008-11-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
124,156,136 |
|
- |
|
| Classon Rolf A |
Director |
– • – |
2008-11-17 |
4 |
B |
$4.01 |
$40,552 |
D/D |
10,000 |
15,961 |
2.39 |
- |
|
| Ando Goran |
Director |
– • – |
2008-11-14 |
4 |
B |
$3.77 |
$56,514 |
D/D |
15,000 |
36,130 |
2.39 |
- |
|
| Renfro Phillip M |
Director |
– • – |
2008-11-14 |
4 |
B |
$3.61 |
$36,429 |
D/D |
10,000 |
25,973 |
2.39 |
- |
|
| Micati Victor P |
Director |
– • – |
2008-11-13 |
4 |
B |
$3.28 |
$49,271 |
D/D |
15,000 |
36,130 |
2.39 |
- |
|
| Salisbury Robert C |
Director |
– • – |
2008-11-13 |
4 |
S |
$3.25 |
$13,098 |
D/D |
(4,030) |
35,161 |
|
- |
|
| Salisbury Robert C |
Director |
– • – |
2008-11-13 |
4 |
B |
$3.19 |
$19,113 |
D/D |
5,970 |
31,131 |
2.39 |
- |
|
| Salisbury Robert C |
Director |
– • – |
2008-11-13 |
4/A |
B |
$3.19 |
$32,211 |
D/D |
10,000 |
35,161 |
2.39 |
- |
|
| Buchalter Jeffrey H |
Chairman, CEO & President |
• • – |
2008-11-13 |
4 |
B |
$3.28 |
$164,035 |
D/D |
50,000 |
453,234 |
2.81 |
- |
|
| Horak Ivan D |
EVP, R&D, Chief Scientific Ofc |
• – – |
2008-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
106,000 |
|
- |
|
| Renfro Phillip M |
Director |
– • – |
2008-07-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,105 |
15,973 |
|
- |
|
| Classon Rolf A |
Director |
– • – |
2008-07-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,105 |
30,825 |
|
- |
|
| Ando Goran |
Director |
– • – |
2008-07-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,105 |
21,130 |
|
- |
|
| Lebuhn Robert |
Director |
– • – |
2008-07-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,105 |
102,024 |
|
- |
|
394 Records found
|
|
Page 11 of 16 |
|
|
